Effect of Probiotics and Prebiotics in Renal Function in Septic Acute Kidney Injury Patients

NCT ID: NCT03877081

Last Updated: 2021-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-04

Study Completion Date

2023-02-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Septic acute kidney injury is a condition associated with highly related to inflammatory molecules. Prebiotics and probiotics have shown to improve inflammatory cascade in animal model; In this study, the investigators propose the use of probiotics to improve the clinical evolution of septic acute kidney injury patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute kidney injury is most commonly caused by sepsis, where endotoxemia and an expanding inflammatory reaction play a key role in its pathogenesis, when this condition is present it is highly related to poor clinical outcomes and higher mortality rates. There is no current specific treatment, and the therapeutic approach is more orientated to complication management. In this study, the investigators propose the use of probiotics to improve the clinical evolution of septic acute kidney injury patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Probiotics Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double blind randomized controlled trial
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotics. Intervention patients

This patients will receive 2 doses of oral probiotics a day, for seven days

Group Type EXPERIMENTAL

Probiotics

Intervention Type BIOLOGICAL

Administration of oral probiotics with 2 doses a day

Placebo group

This patients will receive 2 doses of oral placebo a day, for seven days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Administration of oral placebo with 2 doses a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotics

Administration of oral probiotics with 2 doses a day

Intervention Type BIOLOGICAL

Placebo

Administration of oral placebo with 2 doses a day

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sepsis by SOFA
* Acute kidney injury by KDIGO

Exclusion Criteria

* No presence of sepsis
* No presence of AKI
* Age below 18 years
* Inability or contraindication for oral capsules or probiotics by nasogastric tube
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Civil de Guadalajara

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jonathan Samuel Chavez IƱiguez

MD, Nephrologist, Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HCG

Guadalajara, Jalisco, Mexico

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Mexico

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jonathan Samuel Chavez

Role: primary

3313299609

References

Explore related publications, articles, or registry entries linked to this study.

Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R. Acute kidney injury: an increasing global concern. Lancet. 2013 Jul 13;382(9887):170-9. doi: 10.1016/S0140-6736(13)60647-9. Epub 2013 May 31.

Reference Type BACKGROUND
PMID: 23727171 (View on PubMed)

Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int. 2015 Jan;87(1):46-61. doi: 10.1038/ki.2014.293. Epub 2014 Sep 17.

Reference Type BACKGROUND
PMID: 25229340 (View on PubMed)

Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators. Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int. 2010 Mar;77(6):527-35. doi: 10.1038/ki.2009.502. Epub 2009 Dec 23.

Reference Type BACKGROUND
PMID: 20032961 (View on PubMed)

Nisula S, Kaukonen KM, Vaara ST, Korhonen AM, Poukkanen M, Karlsson S, Haapio M, Inkinen O, Parviainen I, Suojaranta-Ylinen R, Laurila JJ, Tenhunen J, Reinikainen M, Ala-Kokko T, Ruokonen E, Kuitunen A, Pettila V; FINNAKI Study Group. Incidence, risk factors and 90-day mortality of patients with acute kidney injury in Finnish intensive care units: the FINNAKI study. Intensive Care Med. 2013 Mar;39(3):420-8. doi: 10.1007/s00134-012-2796-5. Epub 2013 Jan 5.

Reference Type BACKGROUND
PMID: 23291734 (View on PubMed)

Bagshaw SM, George C, Dinu I, Bellomo R. A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant. 2008 Apr;23(4):1203-10. doi: 10.1093/ndt/gfm744. Epub 2007 Oct 25.

Reference Type BACKGROUND
PMID: 17962378 (View on PubMed)

Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med. 2007 Aug;35(8):1837-43; quiz 1852. doi: 10.1097/01.CCM.0000277041.13090.0A.

Reference Type BACKGROUND
PMID: 17581483 (View on PubMed)

Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, De Bacquer D, Kellum JA. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care. 2006;10(3):R73. doi: 10.1186/cc4915. Epub 2006 May 12.

Reference Type BACKGROUND
PMID: 16696865 (View on PubMed)

Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honore PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015 Aug;41(8):1411-23. doi: 10.1007/s00134-015-3934-7. Epub 2015 Jul 11.

Reference Type BACKGROUND
PMID: 26162677 (View on PubMed)

Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006 Feb;34(2):344-53. doi: 10.1097/01.ccm.0000194725.48928.3a.

Reference Type BACKGROUND
PMID: 16424713 (View on PubMed)

Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011 Jun;79(12):1361-9. doi: 10.1038/ki.2011.42. Epub 2011 Mar 23.

Reference Type BACKGROUND
PMID: 21430640 (View on PubMed)

Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349-55. doi: 10.1159/000337487. Epub 2012 Apr 2.

Reference Type BACKGROUND
PMID: 22473149 (View on PubMed)

Zarjou A, Agarwal A. Sepsis and acute kidney injury. J Am Soc Nephrol. 2011 Jun;22(6):999-1006. doi: 10.1681/ASN.2010050484. Epub 2011 May 12.

Reference Type BACKGROUND
PMID: 21566052 (View on PubMed)

Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, Kellum JA. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock. 2014 Jan;41(1):3-11. doi: 10.1097/SHK.0000000000000052.

Reference Type BACKGROUND
PMID: 24346647 (View on PubMed)

Mehta RL, Bouchard J, Soroko SB, Ikizler TA, Paganini EP, Chertow GM, Himmelfarb J; Program to Improve Care in Acute Renal Disease (PICARD) Study Group. Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Med. 2011 Feb;37(2):241-8. doi: 10.1007/s00134-010-2089-9. Epub 2010 Dec 9.

Reference Type BACKGROUND
PMID: 21152901 (View on PubMed)

Peters E, Antonelli M, Wittebole X, Nanchal R, Francois B, Sakr Y, Vincent JL, Pickkers P. A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit. Crit Care. 2018 Aug 3;22(1):188. doi: 10.1186/s13054-018-2112-z.

Reference Type BACKGROUND
PMID: 30075798 (View on PubMed)

Bellomo R, Kellum JA, Ronco C, Wald R, Martensson J, Maiden M, Bagshaw SM, Glassford NJ, Lankadeva Y, Vaara ST, Schneider A. Acute kidney injury in sepsis. Intensive Care Med. 2017 Jun;43(6):816-828. doi: 10.1007/s00134-017-4755-7. Epub 2017 Mar 31.

Reference Type BACKGROUND
PMID: 28364303 (View on PubMed)

Gomez H, Kellum JA. Sepsis-induced acute kidney injury. Curr Opin Crit Care. 2016 Dec;22(6):546-553. doi: 10.1097/MCC.0000000000000356.

Reference Type BACKGROUND
PMID: 27661757 (View on PubMed)

Dellepiane S, Marengo M, Cantaluppi V. Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies. Crit Care. 2016 Mar 15;20:61. doi: 10.1186/s13054-016-1219-3.

Reference Type BACKGROUND
PMID: 26976392 (View on PubMed)

Mariano F, Cantaluppi V, Stella M, Romanazzi GM, Assenzio B, Cairo M, Biancone L, Triolo G, Ranieri VM, Camussi G. Circulating plasma factors induce tubular and glomerular alterations in septic burns patients. Crit Care. 2008;12(2):R42. doi: 10.1186/cc6848. Epub 2008 Mar 25.

Reference Type BACKGROUND
PMID: 18364044 (View on PubMed)

Pickkers P, Ostermann M, Joannidis M, Zarbock A, Hoste E, Bellomo R, Prowle J, Darmon M, Bonventre JV, Forni L, Bagshaw SM, Schetz M. The intensive care medicine agenda on acute kidney injury. Intensive Care Med. 2017 Sep;43(9):1198-1209. doi: 10.1007/s00134-017-4687-2. Epub 2017 Jan 30.

Reference Type BACKGROUND
PMID: 28138736 (View on PubMed)

Cigarran Guldris S, Gonzalez Parra E, Cases Amenos A. Gut microbiota in chronic kidney disease. Nefrologia. 2017 Jan-Feb;37(1):9-19. doi: 10.1016/j.nefro.2016.05.008. Epub 2016 Aug 21. English, Spanish.

Reference Type BACKGROUND
PMID: 27553986 (View on PubMed)

Vanholder R, Glorieux G. The intestine and the kidneys: a bad marriage can be hazardous. Clin Kidney J. 2015 Apr;8(2):168-79. doi: 10.1093/ckj/sfv004. Epub 2015 Feb 10.

Reference Type BACKGROUND
PMID: 25815173 (View on PubMed)

Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin. 2009 Aug;25(8):1919-30. doi: 10.1185/03007990903069249.

Reference Type BACKGROUND
PMID: 19558344 (View on PubMed)

Icaza-Chavez ME. [Gut microbiota in health and disease]. Rev Gastroenterol Mex. 2013 Oct-Dec;78(4):240-8. doi: 10.1016/j.rgmx.2013.04.004. Epub 2013 Nov 28. Spanish.

Reference Type BACKGROUND
PMID: 24290319 (View on PubMed)

Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.

Reference Type BACKGROUND
PMID: 22992469 (View on PubMed)

Natarajan R, Pechenyak B, Vyas U, Ranganathan P, Weinberg A, Liang P, Mallappallil MC, Norin AJ, Friedman EA, Saggi SJ. Randomized controlled trial of strain-specific probiotic formulation (Renadyl) in dialysis patients. Biomed Res Int. 2014;2014:568571. doi: 10.1155/2014/568571. Epub 2014 Jul 24.

Reference Type BACKGROUND
PMID: 25147806 (View on PubMed)

Miranda Alatriste PV, Urbina Arronte R, Gomez Espinosa CO, Espinosa Cuevas Mde L. Effect of probiotics on human blood urea levels in patients with chronic renal failure. Nutr Hosp. 2014 Mar 1;29(3):582-90. doi: 10.3305/nh.2014.29.3.7179.

Reference Type BACKGROUND
PMID: 24559003 (View on PubMed)

Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015 Nov;88(5):958-66. doi: 10.1038/ki.2015.255. Epub 2015 Sep 16.

Reference Type BACKGROUND
PMID: 26376131 (View on PubMed)

Wanchai K, Pongchaidecha A, Chatsudthipong V, Chattipakorn SC, Chattipakorn N, Lungkaphin A. Role of Gastrointestinal Microbiota on Kidney Injury and the Obese Condition. Am J Med Sci. 2017 Jan;353(1):59-69. doi: 10.1016/j.amjms.2016.11.019. Epub 2016 Nov 17.

Reference Type BACKGROUND
PMID: 28104104 (View on PubMed)

Yoshifuji A, Wakino S, Irie J, Tajima T, Hasegawa K, Kanda T, Tokuyama H, Hayashi K, Itoh H. Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol Dial Transplant. 2016 Mar;31(3):401-12. doi: 10.1093/ndt/gfv353. Epub 2015 Oct 20.

Reference Type BACKGROUND
PMID: 26487672 (View on PubMed)

Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J Ren Nutr. 2005 Jan;15(1):77-80. doi: 10.1053/j.jrn.2004.09.028.

Reference Type BACKGROUND
PMID: 15648012 (View on PubMed)

Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S142-5. doi: 10.1053/ajkd.2003.50104.

Reference Type BACKGROUND
PMID: 12612972 (View on PubMed)

Ando Y, Miyata Y, Tanba K, Saito O, Muto S, Kurosu M, Homma S, Kusano E, Asano Y. [Effect of oral intake of an enteric capsule preparation containing Bifidobacterium longum on the progression of chronic renal failure]. Nihon Jinzo Gakkai Shi. 2003;45(8):759-64. Japanese.

Reference Type BACKGROUND
PMID: 14737993 (View on PubMed)

Ogawa T, Shimada M, Nagano N, Ito K, Ando T, Shimomura Y, Ando Y, Otsuka K. Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Clin Kidney J. 2012 Aug;5(4):373-4. doi: 10.1093/ckj/sfs072. No abstract available.

Reference Type BACKGROUND
PMID: 25874106 (View on PubMed)

Yang J, Summanen PH, Henning SM, Hsu M, Lam H, Huang J, Tseng CH, Dowd SE, Finegold SM, Heber D, Li Z. Xylooligosaccharide supplementation alters gut bacteria in both healthy and prediabetic adults: a pilot study. Front Physiol. 2015 Aug 7;6:216. doi: 10.3389/fphys.2015.00216. eCollection 2015.

Reference Type BACKGROUND
PMID: 26300782 (View on PubMed)

Finegold SM, Li Z, Summanen PH, Downes J, Thames G, Corbett K, Dowd S, Krak M, Heber D. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct. 2014 Mar;5(3):436-45. doi: 10.1039/c3fo60348b.

Reference Type BACKGROUND
PMID: 24513849 (View on PubMed)

Kellum JA, Lameire N; KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013 Feb 4;17(1):204. doi: 10.1186/cc11454.

Reference Type BACKGROUND
PMID: 23394211 (View on PubMed)

Chavez-Iniguez JS, Ibarra-Estrada M, Gallardo-Gonzalez AM, Cisneros-Hernandez A, Claure-Del Granado R, Chavez-Alonso G, Hernandez-Barajas EM, Romero-Munoz AC, Ramos-Avellaneda F, Prieto-Magallanes ML, Plascencia-Cruz M, Tanaka-Gutierrez JA, Perez-Hernandez C, Navarro-Blackaller G, Medina-Gonzalez R, Alcantar-Vallin L, Renoirte-Lopez K, Garcia-Garcia G. Probiotics in septic acute kidney injury, a double blind, randomized control trial. Ren Fail. 2023;45(2):2260003. doi: 10.1080/0886022X.2023.2260003. Epub 2023 Sep 19.

Reference Type DERIVED
PMID: 37724527 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AKI and Probiotics

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics in IgA Nephropathy
NCT01781312 UNKNOWN NA
Prebiotic Effects in Healthy Toddlers
NCT05783141 RECRUITING NA